Relmada Therapeutics Holds Annual Stockholders Meeting

Relmada Therapeutics ( (RLMD) ) just unveiled an update.

On May 23, 2025, Relmada Therapeutics held its Annual Meeting of Stockholders, where approximately 53.6% of eligible shares were voted. Key outcomes included the election of John Glasspool as a Class I Director, the ratification of CBIZ CPAs P.C. as independent auditors for 2025, and the approval of an amendment to increase shares available under the 2021 Equity Incentive Plan by 2,000,000.

The most recent analyst rating on (RLMD) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.

Spark’s Take on RLMD Stock

According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.

Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.

To see Spark’s full report on RLMD stock, click here.

More about Relmada Therapeutics

Relmada Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing treatments for central nervous system disorders. The company is engaged in creating novel therapies to address unmet medical needs in this market segment.

Average Trading Volume: 1,832,185

Technical Sentiment Signal: Sell

Current Market Cap: $21.22M

See more data about RLMD stock on TipRanks’ Stock Analysis page.